Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Wave Life Sciences (WVE), a clinical-stage biotechnology company specializing in RNA medicines, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Paul Bolno, MD, MBA, will deliver a presentation on Monday, January 13, 2025, at 9:45 a.m. PT / 12:45 p.m. ET in San Francisco, CA.

Investors and interested parties can access a live webcast of the presentation through the company's Investor Relations website under the 'Investor Events' section. A replay will be available for a time after the event.

CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 43^rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13, 2025, at 9:45 a.m. PT / 12:45 p.m. ET.

A live webcast of this presentation can be accessed by visiting “Investor Events” on the Investor Relations section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. A replay of this presentation will be archived and available on the site for a limited time following the event.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X (formerly Twitter) and LinkedIn.

Investor Contact:
Kate Rausch
+1 617-949-4827
krausch@wavelifesci.com

Media Contact:
Alicia Suter
+1 617-949-4817
asuter@wavelifesci.com

FAQ

When is Wave Life Sciences (WVE) presenting at the 2025 J.P. Morgan Healthcare Conference?

Wave Life Sciences is scheduled to present on Monday, January 13, 2025, at 9:45 a.m. PT / 12:45 p.m. ET in San Francisco, CA.

How can investors watch Wave Life Sciences' presentation at the J.P. Morgan Healthcare Conference?

Investors can watch the live webcast by visiting the 'Investor Events' section on Wave Life Sciences' Investor Relations website at ir.wavelifesciences.com/events-publications/events.

Will Wave Life Sciences' J.P. Morgan Healthcare Conference presentation be available for replay?

Yes, a replay of the presentation will be archived and available on the company's website for a time following the event.

What is Wave Life Sciences' (WVE) primary focus as a biotechnology company?

Wave Life Sciences is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health.